CFM
ZVRA icon

Cornerstone Financial Management’s Zevra Therapeutics ZVRA Stock Holding History

Cornerstone Financial Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Hold
115
– – ﹤0.01% 910
2026
Q1 		$1.07K Hold
115
– – ﹤0.01% 939
2025
Q4 		$1.03K Buy
+115
New +$1.09K ﹤0.01% 919

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cornerstone Financial Management's ZVRA Position: Q2 2026 in Review

Cornerstone Financial Management held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 115 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

Cornerstone Financial Management first reported a position in ZVRA in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Cornerstone Financial Management held 115 shares of Zevra Therapeutics worth $1.65K as of Q2 2026.
  • Cornerstone Financial Management left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #910 holding.
  • Cornerstone Financial Management first reported a position in Zevra Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.